Sign up Australia
Proactive Investors - Run By Investors For Investors

Regeneus takes step towards bringing Progenza osteoarthritis treatment to Europe

Progenza has been granted Advanced Therapy Medicinal Product designation.
Knee pain
The stem cell technology has been developed for the treatment of knee osteoarthritis

Regeneus Ltd (ASX:RGS) has taken a step towards bringing its Progenza osteoarthritis treatment to Europe after being granted Advanced Therapy Medicinal Product (ATMP) designation.

Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions.

The classification was granted by the European Medicines Agency’s Committee for Advanced Therapies following consultation with the European Commission.

“Important to have regulatory clarity”

John Martin, chief executive officer, said “The granting of the ATMP classification for Progenza, is a step towards bringing Progenza to Europe as a novel cell therapy treatment for osteoarthritis.

“It’s important to have regulatory clarity as we invest in the development of Progenza.”

ATMP classified products are novel regenerative therapies that combine aspects of medicine, cell biology, science and engineering.

They are presented as having properties with a view to regenerating, repairing or replacing a human tissue.

ATMPs comprise cell and gene therapies and tissue-engineered products.

10-15% of all adults over 60 are affected

The World Health Organisation estimates that 10-15% of all adults over 60 have some degree of osteoarthritis, with prevalence higher in women than men.

Given that there are few preventative and therapeutic options for osteoarthritis and that the European population is ageing, the burden of osteoarthritis is predicted to rise.

Safety trial meets primary endpoints

Results of a phase I safety trial of Progenza in knee osteoarthritis met primary endpoints of safety and tolerability.

Secondary endpoints showed a significant, rapid and sustained reduction in knee pain, and significant improvement in cartilage volume compared to placebo, with positive signs of disease modification.

Reduced inflammation and pain

The Progenza cells work by secreting cytokines, growth factors and exosomes that act in concert to reduce inflammation and pain and encourage accelerated healing and repair of damaged or diseased tissue.

Progenza is produced from expanded mesenchymal stem cells (MSCs) extracted from adipose (fat) tissue from a healthy donor who has been extensively screened.

Unlike other stem cell products, Progenza includes secretions from MSCs that improve viability and functionality of the cells during the freezing and thawing process.

Regeneus has shown that the combination of cells and secretions has a more powerful therapeutic effect than cells alone.

The company has demonstrated the capacity to produce millions of therapeutic doses of Progenza from a single donor which helps avoid the need to pool donor material and seek multiple donors.

READ: Regeneus granted key cancer treatment patent in Japan

Regeneus is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies.

These are aimed at addressing significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

READ: Regeneus shares rise as results show Sygenus gel successfully fights acne

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector
July 26 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use